MII IG Kerndatensatz-Modul Onkologie
2027.0.0-ballot.1 -
Germany
MII IG Kerndatensatz-Modul Onkologie
2027.0.0-ballot.1 -
Germany
This page is part of the MII IG Kerndatensatz-Modul Onkologie (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions
| Active Stand: 2024-12-12 |
{
"resourceType" : "ConceptMap",
"id" : "mii-cm-onko-atc-transitions-2021",
"meta" : {
"extension" : [
{
"url" : "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-license",
"valueCode" : "CC-BY-4.0"
},
{
"extension" : [
{
"url" : "packageId",
"valueId" : "de.medizininformatikinitiative.kerndatensatz.onkologie"
},
{
"url" : "version",
"valueString" : "2027.0.0-ballot.1"
},
{
"url" : "uri",
"valueUri" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko"
}
],
"url" : "http://hl7.org/fhir/StructureDefinition/package-source"
}
],
"profile" : [
🔗 "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-shareableconceptmap"🔗 ,
"http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-publishableconceptmap"
]
},
"language" : "de",
"text" : {
"status" : "generated",
"div" : "<div xml:lang=\"de\" lang=\"de\"><hr/><p><b>German</b></p><hr/><p class=\"res-header-id\"><b>Generated Narrative: ConceptMap mii-cm-onko-atc-transitions-2021</b></p><a name=\"de-mii-cm-onko-atc-transitions-2021\"> </a><a name=\"de-hcmii-cm-onko-atc-transitions-2021\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profiles: <a href=\"http://hl7.org/fhir/uv/crmi/STU2/StructureDefinition-crmi-shareableconceptmap.html\">CRMI Shareable ConceptMap</a>, <a href=\"http://hl7.org/fhir/uv/crmi/STU2/StructureDefinition-crmi-publishableconceptmap.html\">CRMI Publishable ConceptMap</a></p></div><p>Mapping from <a href=\"ValueSet-mii-vs-onko-systemische-therapie-substanzen-2020.html\">MII VS Onkologie Systemische Therapie Substanzen ATC 2020</a> to <a href=\"ValueSet-mii-vs-onko-systemische-therapie-substanzen-2021.html\">MII VS Onkologie Systemische Therapie Substanzen ATC 2021</a></p><br/><p>Mapping from <code>http://fhir.de/CodeSystem/bfarm/atc</code> (Atc) to <code>http://fhir.de/CodeSystem/bfarm/atc</code> (Atc)</p><table class=\"grid\"><tr><td><b>Source Code</b></td><td><b>Relationship</b></td><td><b>Target Code</b></td><td><b>Comment</b></td></tr><tr><td>L01XE01 (Imatinib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EA01 (Imatinib)</td><td>Reklassifizierung zu BCR-ABL Tyrosinkinase-Inhibitoren</td></tr><tr><td>L01XE06 (Dasatinib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EA02 (Dasatinib)</td><td/></tr><tr><td>L01XE08 (Nilotinib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EA03 (Nilotinib)</td><td/></tr><tr><td>L01XE14 (Bosutinib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EA04 (Bosutinib)</td><td/></tr><tr><td>L01XE24 (Ponatinib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EA05 (Ponatinib)</td><td/></tr><tr><td>L01XE02 (Gefitinib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EB01 (Gefitinib)</td><td>Reklassifizierung zu EGFR Tyrosinkinase-Inhibitoren</td></tr><tr><td>L01XE03 (Erlotinib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EB02 (Erlotinib)</td><td/></tr><tr><td>L01XE13 (Afatinib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EB03 (Afatinib)</td><td/></tr><tr><td>L01XE35 (Osimertinib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EB04 (Osimertinib)</td><td/></tr><tr><td>L01XE15 (Vemurafenib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EC01 (Vemurafenib)</td><td>Reklassifizierung zu BRAF-Inhibitoren</td></tr><tr><td>L01XE23 (Dabrafenib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EC02 (Dabrafenib)</td><td/></tr><tr><td>L01XE46 (Encorafenib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EC03 (Encorafenib)</td><td/></tr><tr><td>L01XE16 (Crizotinib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01ED01 (Crizotinib)</td><td>Reklassifizierung zu ALK-Inhibitoren</td></tr><tr><td>L01XE28 (Ceritinib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01ED02 (Ceritinib)</td><td/></tr><tr><td>L01XE36 (Alectinib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01ED03 (Alectinib)</td><td/></tr><tr><td>L01XE43 (Brigatinib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01ED04 (Brigatinib)</td><td/></tr><tr><td>L01XE44 (Lorlatinib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01ED05 (Lorlatinib)</td><td/></tr><tr><td>L01XE25 (Trametinib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EE01 (Trametinib)</td><td>Reklassifizierung zu MEK-Inhibitoren</td></tr><tr><td>L01XE38 (Cobimetinib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EE02 (Cobimetinib)</td><td/></tr><tr><td>L01XE41 (Binimetinib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EE03 (Binimetinib)</td><td/></tr><tr><td>L01XE33 (Palbociclib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EF01 (Palbociclib)</td><td>Reklassifizierung zu CDK4/6-Inhibitoren</td></tr><tr><td>L01XE42 (Ribociclib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EF02 (Ribociclib)</td><td/></tr><tr><td>L01XE50 (Abemaciclib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EF03 (Abemaciclib)</td><td/></tr><tr><td>L01XE09 (Temsirolimus)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EG01 (Temsirolimus)</td><td>Reklassifizierung zu mTOR-Inhibitoren</td></tr><tr><td>L01XE10 (Everolimus)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EG02 (Everolimus)</td><td/></tr><tr><td>L01XE07 (Lapatinib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EH01 (Lapatinib)</td><td>Reklassifizierung zu HER2-Inhibitoren</td></tr><tr><td>L01XE45 (Neratinib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EH02 (Neratinib)</td><td/></tr><tr><td>L01XE18 (Ruxolitinib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EJ01 (Ruxolitinib)</td><td>Reklassifizierung zu JAK-Inhibitoren</td></tr><tr><td>L01XE17 (Axitinib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EK01 (Axitinib)</td><td>Reklassifizierung zu VEGFR-Inhibitoren</td></tr><tr><td>L01XE34 (Tivozanib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EK03 (Tivozanib)</td><td/></tr><tr><td>L01XE27 (Ibrutinib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EL01 (Ibrutinib)</td><td>Reklassifizierung zu BTK-Inhibitoren</td></tr><tr><td>L01XE51 (Acalabrutinib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EL02 (Acalabrutinib)</td><td/></tr><tr><td>L01XX47 (Idelalisib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EM01 (Idelalisib)</td><td>Reklassifizierung zu PI3K-Inhibitoren</td></tr><tr><td>L01XX61 (Copanlisib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EM02 (Copanlisib)</td><td/></tr><tr><td>L01XE04 (Sunitinib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EX01 (Sunitinib)</td><td>Reklassifizierung zu andere Proteinkinase-Inhibitoren</td></tr><tr><td>L01XE05 (Sorafenib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EX02 (Sorafenib)</td><td/></tr><tr><td>L01XE12 (Vandetanib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EX04 (Vandetanib)</td><td/></tr><tr><td>L01XE21 (Regorafenib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EX05 (Regorafenib)</td><td/></tr><tr><td>L01XE26 (Cabozantinib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EX07 (Cabozantinib)</td><td/></tr><tr><td>L01XE29 (Lenvatinib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EX08 (Lenvatinib)</td><td/></tr><tr><td>L01XE31 (Nintedanib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EX09 (Nintedanib)</td><td/></tr><tr><td>L01XE39 (Midostaurin)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EX10 (Midostaurin)</td><td/></tr><tr><td>L01XE52 (Quizartinib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EX11 (Quizartinib)</td><td/></tr><tr><td>L01XE53 (Larotrectinib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EX12 (Larotrectinib)</td><td/></tr><tr><td>L01XE54 (Gilteritinib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01EX13 (Gilteritinib)</td><td/></tr><tr><td>L01XX14 (Tretinoin)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01XF01 (Tretinoin)</td><td>Reklassifizierung zu Retinoide</td></tr><tr><td>L01XX22 (Alitretinoin)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01XF02 (Alitretinoin)</td><td/></tr><tr><td>L01XX25 (Bexaroten)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01XF03 (Bexaroten)</td><td/></tr><tr><td>L01XX32 (Bortezomib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01XG01 (Bortezomib)</td><td>Reklassifizierung zu Proteasom-Inhibitoren</td></tr><tr><td>L01XX45 (Carfilzomib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01XG02 (Carfilzomib)</td><td/></tr><tr><td>L01XX50 (Ixazomib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01XG03 (Ixazomib)</td><td/></tr><tr><td>L01XX38 (Vorinostat)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01XH01 (Vorinostat)</td><td>Reklassifizierung zu Histon-Deacetylase-Inhibitoren</td></tr><tr><td>L01XX39 (Romidepsin)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01XH02 (Romidepsin)</td><td/></tr><tr><td>L01XX42 (Panobinostat)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01XH03 (Panobinostat)</td><td/></tr><tr><td>L01XX49 (Belinostat)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01XH04 (Belinostat)</td><td/></tr><tr><td>L01XX43 (Vismodegib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01XJ01 (Vismodegib)</td><td>Reklassifizierung zu Hedgehog-Signalweg-Inhibitoren</td></tr><tr><td>L01XX63 (Glasdegib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01XJ03 (Glasdegib)</td><td/></tr><tr><td>L01XX46 (Olaparib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01XK01 (Olaparib)</td><td>Reklassifizierung zu PARP-Inhibitoren</td></tr><tr><td>L01XX54 (Niraparib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01XK02 (Niraparib)</td><td/></tr><tr><td>L01XX60 (Talazoparib)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01XK04 (Talazoparib)</td><td/></tr><tr><td>L01XX17 (Topotecan)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01CE01 (Topotecan)</td><td>Reklassifizierung zu Topoisomerase-I-Inhibitoren</td></tr><tr><td>L01XX19 (Irinotecan)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01CE02 (Irinotecan)</td><td/></tr></table></div>"
},
"extension" : [
{
"url" : "http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability",
"valueCode" : "shareable"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability",
"valueCode" : "publishable"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-versionPolicy",
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/artifact-version-policy-codes",
"code" : "package",
"display" : "Package"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/resource-approvalDate",
"valueDate" : "2026-09-15"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-topic",
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C3262"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-author",
"valueContactDetail" : {
"telecom" : [
{
"system" : "email",
"value" : "thomas.debertshaeuser@charite.de"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-editor",
"valueContactDetail" : {
"name" : "Taskforce Core Data Set"
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-reviewer",
"valueContactDetail" : {
"name" : "Interoperability Working Group",
"telecom" : [
{
"system" : "url",
"value" : "https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-reviewer",
"valueContactDetail" : {
"name" : "National Steering Committee",
"telecom" : [
{
"system" : "url",
"value" : "https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-endorser",
"valueContactDetail" : {
"name" : "Interoperability Working Group",
"telecom" : [
{
"system" : "url",
"value" : "https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-endorser",
"valueContactDetail" : {
"name" : "National Steering Committee",
"telecom" : [
{
"system" : "url",
"value" : "https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-versionAlgorithm",
"valueCoding" : {
"system" : "http://hl7.org/fhir/version-algorithm",
"code" : "semver",
"display" : "SemVer"
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/resource-effectivePeriod",
"valuePeriod" : {
"start" : "2027"
}
}
],
"url" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ConceptMap/mii-cm-onko-atc-transitions-2021",
"version" : "2027.0.0-ballot.1",
"name" : "MII_CM_Onko_ATC_Transitions_2021",
"title" : "MII CM Onko ATC Code Changes 2020 to 2021",
"status" : "active",
"experimental" : false,
"date" : "2024-12-12",
"publisher" : "Medizininformatik Initiative",
"contact" : [
{
"name" : "Medizininformatik Initiative",
"telecom" : [
{
"system" : "url",
"value" : "https://www.medizininformatik-initiative.de/"
}
]
}
],
"description" : "Diese ConceptMap dokumentiert ausschließlich die ATC-Code-Änderungen von 2020 zu 2021. Im Jahr 2021 erfolgte eine umfassende Reorganisation der ATC-Klassifikation für onkologische Substanzen mit Umkodierung von über 60 Wirkstoffen.",
"jurisdiction" : [
{
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "DE",
"display" : "Germany"
}
]
}
],
"purpose" : "Migration von ATC-Codes für Substanzen, die 2021 umkodiert wurden. Enthält nur geänderte Codes, keine neuen oder unveränderten Einträge.",
"sourceCanonical" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2020",
"targetCanonical" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2021",
"group" : [
{
"source" : "http://fhir.de/CodeSystem/bfarm/atc",
"target" : "http://fhir.de/CodeSystem/bfarm/atc",
"element" : [
{
"code" : "L01XE01",
"display" : "Imatinib",
"target" : [
{
"code" : "L01EA01",
"display" : "Imatinib",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu BCR-ABL Tyrosinkinase-Inhibitoren"
}
]
},
{
"code" : "L01XE06",
"display" : "Dasatinib",
"target" : [
{
"code" : "L01EA02",
"display" : "Dasatinib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE08",
"display" : "Nilotinib",
"target" : [
{
"code" : "L01EA03",
"display" : "Nilotinib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE14",
"display" : "Bosutinib",
"target" : [
{
"code" : "L01EA04",
"display" : "Bosutinib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE24",
"display" : "Ponatinib",
"target" : [
{
"code" : "L01EA05",
"display" : "Ponatinib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE02",
"display" : "Gefitinib",
"target" : [
{
"code" : "L01EB01",
"display" : "Gefitinib",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu EGFR Tyrosinkinase-Inhibitoren"
}
]
},
{
"code" : "L01XE03",
"display" : "Erlotinib",
"target" : [
{
"code" : "L01EB02",
"display" : "Erlotinib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE13",
"display" : "Afatinib",
"target" : [
{
"code" : "L01EB03",
"display" : "Afatinib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE35",
"display" : "Osimertinib",
"target" : [
{
"code" : "L01EB04",
"display" : "Osimertinib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE15",
"display" : "Vemurafenib",
"target" : [
{
"code" : "L01EC01",
"display" : "Vemurafenib",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu BRAF-Inhibitoren"
}
]
},
{
"code" : "L01XE23",
"display" : "Dabrafenib",
"target" : [
{
"code" : "L01EC02",
"display" : "Dabrafenib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE46",
"display" : "Encorafenib",
"target" : [
{
"code" : "L01EC03",
"display" : "Encorafenib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE16",
"display" : "Crizotinib",
"target" : [
{
"code" : "L01ED01",
"display" : "Crizotinib",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu ALK-Inhibitoren"
}
]
},
{
"code" : "L01XE28",
"display" : "Ceritinib",
"target" : [
{
"code" : "L01ED02",
"display" : "Ceritinib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE36",
"display" : "Alectinib",
"target" : [
{
"code" : "L01ED03",
"display" : "Alectinib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE43",
"display" : "Brigatinib",
"target" : [
{
"code" : "L01ED04",
"display" : "Brigatinib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE44",
"display" : "Lorlatinib",
"target" : [
{
"code" : "L01ED05",
"display" : "Lorlatinib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE25",
"display" : "Trametinib",
"target" : [
{
"code" : "L01EE01",
"display" : "Trametinib",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu MEK-Inhibitoren"
}
]
},
{
"code" : "L01XE38",
"display" : "Cobimetinib",
"target" : [
{
"code" : "L01EE02",
"display" : "Cobimetinib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE41",
"display" : "Binimetinib",
"target" : [
{
"code" : "L01EE03",
"display" : "Binimetinib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE33",
"display" : "Palbociclib",
"target" : [
{
"code" : "L01EF01",
"display" : "Palbociclib",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu CDK4/6-Inhibitoren"
}
]
},
{
"code" : "L01XE42",
"display" : "Ribociclib",
"target" : [
{
"code" : "L01EF02",
"display" : "Ribociclib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE50",
"display" : "Abemaciclib",
"target" : [
{
"code" : "L01EF03",
"display" : "Abemaciclib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE09",
"display" : "Temsirolimus",
"target" : [
{
"code" : "L01EG01",
"display" : "Temsirolimus",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu mTOR-Inhibitoren"
}
]
},
{
"code" : "L01XE10",
"display" : "Everolimus",
"target" : [
{
"code" : "L01EG02",
"display" : "Everolimus",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE07",
"display" : "Lapatinib",
"target" : [
{
"code" : "L01EH01",
"display" : "Lapatinib",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu HER2-Inhibitoren"
}
]
},
{
"code" : "L01XE45",
"display" : "Neratinib",
"target" : [
{
"code" : "L01EH02",
"display" : "Neratinib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE18",
"display" : "Ruxolitinib",
"target" : [
{
"code" : "L01EJ01",
"display" : "Ruxolitinib",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu JAK-Inhibitoren"
}
]
},
{
"code" : "L01XE17",
"display" : "Axitinib",
"target" : [
{
"code" : "L01EK01",
"display" : "Axitinib",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu VEGFR-Inhibitoren"
}
]
},
{
"code" : "L01XE34",
"display" : "Tivozanib",
"target" : [
{
"code" : "L01EK03",
"display" : "Tivozanib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE27",
"display" : "Ibrutinib",
"target" : [
{
"code" : "L01EL01",
"display" : "Ibrutinib",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu BTK-Inhibitoren"
}
]
},
{
"code" : "L01XE51",
"display" : "Acalabrutinib",
"target" : [
{
"code" : "L01EL02",
"display" : "Acalabrutinib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XX47",
"display" : "Idelalisib",
"target" : [
{
"code" : "L01EM01",
"display" : "Idelalisib",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu PI3K-Inhibitoren"
}
]
},
{
"code" : "L01XX61",
"display" : "Copanlisib",
"target" : [
{
"code" : "L01EM02",
"display" : "Copanlisib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE04",
"display" : "Sunitinib",
"target" : [
{
"code" : "L01EX01",
"display" : "Sunitinib",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu andere Proteinkinase-Inhibitoren"
}
]
},
{
"code" : "L01XE05",
"display" : "Sorafenib",
"target" : [
{
"code" : "L01EX02",
"display" : "Sorafenib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE12",
"display" : "Vandetanib",
"target" : [
{
"code" : "L01EX04",
"display" : "Vandetanib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE21",
"display" : "Regorafenib",
"target" : [
{
"code" : "L01EX05",
"display" : "Regorafenib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE26",
"display" : "Cabozantinib",
"target" : [
{
"code" : "L01EX07",
"display" : "Cabozantinib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE29",
"display" : "Lenvatinib",
"target" : [
{
"code" : "L01EX08",
"display" : "Lenvatinib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE31",
"display" : "Nintedanib",
"target" : [
{
"code" : "L01EX09",
"display" : "Nintedanib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE39",
"display" : "Midostaurin",
"target" : [
{
"code" : "L01EX10",
"display" : "Midostaurin",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE52",
"display" : "Quizartinib",
"target" : [
{
"code" : "L01EX11",
"display" : "Quizartinib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE53",
"display" : "Larotrectinib",
"target" : [
{
"code" : "L01EX12",
"display" : "Larotrectinib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XE54",
"display" : "Gilteritinib",
"target" : [
{
"code" : "L01EX13",
"display" : "Gilteritinib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XX14",
"display" : "Tretinoin",
"target" : [
{
"code" : "L01XF01",
"display" : "Tretinoin",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu Retinoide"
}
]
},
{
"code" : "L01XX22",
"display" : "Alitretinoin",
"target" : [
{
"code" : "L01XF02",
"display" : "Alitretinoin",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XX25",
"display" : "Bexaroten",
"target" : [
{
"code" : "L01XF03",
"display" : "Bexaroten",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XX32",
"display" : "Bortezomib",
"target" : [
{
"code" : "L01XG01",
"display" : "Bortezomib",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu Proteasom-Inhibitoren"
}
]
},
{
"code" : "L01XX45",
"display" : "Carfilzomib",
"target" : [
{
"code" : "L01XG02",
"display" : "Carfilzomib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XX50",
"display" : "Ixazomib",
"target" : [
{
"code" : "L01XG03",
"display" : "Ixazomib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XX38",
"display" : "Vorinostat",
"target" : [
{
"code" : "L01XH01",
"display" : "Vorinostat",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu Histon-Deacetylase-Inhibitoren"
}
]
},
{
"code" : "L01XX39",
"display" : "Romidepsin",
"target" : [
{
"code" : "L01XH02",
"display" : "Romidepsin",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XX42",
"display" : "Panobinostat",
"target" : [
{
"code" : "L01XH03",
"display" : "Panobinostat",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XX49",
"display" : "Belinostat",
"target" : [
{
"code" : "L01XH04",
"display" : "Belinostat",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XX43",
"display" : "Vismodegib",
"target" : [
{
"code" : "L01XJ01",
"display" : "Vismodegib",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu Hedgehog-Signalweg-Inhibitoren"
}
]
},
{
"code" : "L01XX63",
"display" : "Glasdegib",
"target" : [
{
"code" : "L01XJ03",
"display" : "Glasdegib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XX46",
"display" : "Olaparib",
"target" : [
{
"code" : "L01XK01",
"display" : "Olaparib",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu PARP-Inhibitoren"
}
]
},
{
"code" : "L01XX54",
"display" : "Niraparib",
"target" : [
{
"code" : "L01XK02",
"display" : "Niraparib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XX60",
"display" : "Talazoparib",
"target" : [
{
"code" : "L01XK04",
"display" : "Talazoparib",
"equivalence" : "equivalent"
}
]
},
{
"code" : "L01XX17",
"display" : "Topotecan",
"target" : [
{
"code" : "L01CE01",
"display" : "Topotecan",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu Topoisomerase-I-Inhibitoren"
}
]
},
{
"code" : "L01XX19",
"display" : "Irinotecan",
"target" : [
{
"code" : "L01CE02",
"display" : "Irinotecan",
"equivalence" : "equivalent"
}
]
}
]
}
]
}